Abstract
Purpose
Pentamidine is an anti-protozoal cationic aromatic diamidine drug and has been reported to exhibit anticancer properties. We aimed to identify the effect of pentamidine on proliferation and migration of human ovarian cancer (OC) cell lines and the related mechanisms.
Methods
HO8910 and Caov3 ovarian cancer cells were treated with pentamidine. MTS and colony formation assays were used to detect the proliferation ability of cells. The migration of cells was detected using wound healing and transwell assays. The protein levels of PTEN, phosphorylated Akt, Akt, N-cadherin, E-cadherin and snail were detected by Western blotting. Immunoprecipitation and Western blotting were used to detect ubiquitination levels of PTEN.
Results
Our findings revealed that pentamidine inhibited both proliferation and migration of OC cells. Further investigation found that pentamidine increased the protein expression of PTEN and reduced phosphorylation levels of AKT in OC cells. Pentamidine treatment modulated PTEN stability through the ubiquitin/proteasome pathway. In addition, pentamidine inhibited the expression of N-cadherin and snail, and increased E-cadherin expression in a dose-dependent manner.
Conclusion
Pentamidine is involved in the maintenance of PTEN protein stability and suppresses proliferation and migration of OC cells.
Keywords:
Abbreviations
OC, ovarian cancer; PTEN, phosphatase and tensin homologue deleted on chromosome ten; TEP1, TGFβ-regulated and epithelial cell-enriched phosphatase; MMAC1, mutated in multiple advanced cancers; ATCC, American Type Culture Collection; EMT, epithelial–mesenchymal transition; PRL-3, phosphatase of regenerating liver-3; PIP3, phosphatidylinositol (3,4,5)-trisphosphate; PIP2, phosphatidylinositol (4,5)-trisphosphate; AIDS, acquired immune deficiency syndrome; MDR, Multi-drug resistance; CHX, cycloheximide.
Disclosure
The authors report no conflicts of interest in this work.